RT Journal Article
SR Electronic
T1 Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2022.05.03.490409
DO 10.1101/2022.05.03.490409
A1 Daichi Yamasoba
A1 Yusuke Kosugi
A1 Izumi Kimura
A1 Shigeru Fujita
A1 Keiya Uriu
A1 Jumpei Ito
A1 Kei Sato
A1 The Genotype to Phenotype Japan (G2P-Japan) Consortium
YR 2022
UL http://biorxiv.org/content/early/2022/05/03/2022.05.03.490409.abstract
AB As of May 2022, Omicron BA.2 variant is the most dominant variant in the world. Thereafter, Omicron subvariants have emerged and some of them began outcompeting BA.2 in multiple countries. For instance, Omicron BA.2.11, BA.2.12.1 and BA.4/5 subvariants are becoming dominant in France, the USA and South Africa, respectively. In this study, we evaluated the sensitivity of these new Omicron subvariants (BA.2.11, BA.2.12.1 and BA.4/5) to eight therapeutic monoclonal antibodies (bamlanivimab, bebtelovimab, casirivimab, cilgavimab, etesevimab, imdevimab, sotrovimab and tixagevimab). Notably, we showed that although cilgavimab is antiviral against BA.2, BA.4/5 exhibits higher resistance to this antibody compared to BA.2. Since mutations are accumulated in the spike proteins of newly emerging SARS-CoV-2 variants, we suggest the importance of rapid evaluation of the efficiency of therapeutic monoclonal antibodies against novel SARS-CoV-2 variants.Competing Interest StatementThe authors have declared no competing interest.